SCHEMBL6354045

SCHEMBL6354045

CN1CCN(c2cncc(-c3ccoc3)c2)CC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 5/20 0.53
CYP2D6 P10635 4/20 0.53
ALOX15 P16050 3/20 0.53
CYP3A4 P08684 3/20 0.53
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
CYP2C19 P33261 1/20 0.53
ALDH1A1 P00352 3/20 0.51
HSD17B10 Q99714 2/20 0.51
USP2 O75604 2/20 0.49
CLK4 Q9HAZ1 2/20 0.49
HIF1A Q16665 1/20 0.49
HRH1 P35367 1/20 0.47
HRH4 Q9H3N8 1/20 0.47
HRH3 Q9Y5N1 1/20 0.47
HTR1A P08908 2/20 0.47
DRD2 P14416 2/20 0.47
HTR2A P28223 2/20 0.47
HTR7 P34969 2/20 0.47
HTR6 P50406 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6350290 0.83 CHRNB2 (0.51) CYP1A2CYP2D6CYP3A4ALDH1A1HSD17B10
SCHEMBL6350323 0.79 MELK (0.57) CYP1A2CYP2C19HRH4CHEK1CYP11B2
SCHEMBL3453906 0.79 CHEK1 (0.58) HRH4CHEK1CYP11B2
SCHEMBL6352719 0.77 CYP1A2 (0.53) CYP1A2CYP2D6ALOX15CYP3A4MEN1
SCHEMBL6353700 0.76 MET (0.56) HRH1HRH4HRH3CHEK1HDAC3
SCHEMBL6347039 0.75 CYP2A6 (0.57) HRH1HRH4HRH3DRD2HTR6
SCHEMBL4620360 0.75 FYN (0.69) CYP1A2CYP2D6ALOX15CYP3A4MEN1
SCHEMBL6357589 0.74 CHEK1 (0.53) CHEK1CYP11B2
SCHEMBL2385322 0.74 CYP1A2 (0.65) CYP1A2CYP2D6ALOX15CYP3A4MEN1
SCHEMBL6354314 0.74 MELK (0.52) CHEK1CYP11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6897219-B2 Heteroaryl diazacycloalkanes, their preparation and use NEUROSEARCH A/S (DK) 2005-05-24 US disclosed
US-6825189-B1 TREATING WITHDRAWAL SYMPTOMS CAUSED BY SMOKING CESSATION NEUROSEARCH A/S (DK) 2004-11-30 US disclosed
US-20040072823-A1 Heteroaryl diazacycloalkanes, their preparation and use; NEUROSEARCH A/S 2004-04-15 US disclosed
CN-1131211-C Heteroaryl diazacycloalkanes as cholinergic ligands at nicotinic acetylcholine receptors NEUROSEARCH AS (DK) 2003-12-17 CN disclosed
CN-1277604-A Heteroaryl diazacycloalkanes as cholinergic ligands at nicotinic acetylcholine receptors NEUROSEARCH AS (DK) 2000-12-20 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040072823-A1 Heteroaryl diazacycloalkanes, their preparation and use; OGFR, CBR3, OGFRL1 CYP1A2 162/4885CYP2D6 95/4885ALOX15 2067/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.